| abstract |
The present invention is related to a group of small organic molecules that possess arylidene uracil moiety and exhibit anticancer activity. More particularly, the present invention is related to arylidene uracil compounds, which have a potential to show a better anticancer activity with lower concentrations than present compounds in cancer treatment, thus causing less damage to healthy cells and less side effects (nausea, hair loss, anemia, etc.). |